Wall Street Journal (press release) ... United States Court of Appeals for the Federal Circuit has granted a motion by AstraZeneca to enjoin Actavis from further distribution of its generic version of AstraZeneca's Pulmicort RESPULES(R) ( budesonide inhalation suspension) 0.25, 0.5 mg ... and more »
Reuters Breo would also compete with AstraZeneca Plc's twice-a-day Symbicort, an inhaled combination of the corticosteroid budesonide , and the long-acting beta-agonist...
